Delivery Order SPE2DR25D3003-SPE2DR26F5QB3
Award Date 11/20/25
Potential Completion Date 11/21/25
Potential Value $2.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $3,369.92 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on August 13, 2025, with an ultimate completion date of August 14, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 years and older. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 11, 2025, with completion expected by September 12, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and older,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,263.72 for HEPLISAV-B 20 MCG/0.5 ML syringes on June 4, 2025, with an ultimate completion date of June 5, 2025. This competitively awarded, firm fixed-price contract is unset-aside and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing a routine pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes with a ceiling value of $2,692.12. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 15, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged...
- The Defense Logistics Agency awarded a delivery order valued at $127,248.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization in adults. This delivery order is a...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...
- The Defense Logistics Agency awarded a delivery order valued at $105,310.00 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed price delivery order was awarded without set-aside designation through competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with a completion date of June 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order was placed to support federal medical procurement needs, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...